Niagen Bioscience (NAGE) Non-Current Debt (2016)

Niagen Bioscience (NAGE) posted quarterly Non-Current Debt of $3.3 million for Q1 2016.

Niagen Bioscience (NAGE) Non-Current Debt (2016) Analysis & Trends

Niagen Bioscience (NAGE) has reported Non-Current Debt for 1 consecutive years, with $3.3 million the latest figure, recorded in Q1 2016.

In Q1 2016, Non-Current Debt changed N/A year-over-year to $3.3 million; the TTM figure through Jan 2016 stood at $3.3 million (changed N/A YoY), while the FY2016 annual figure was $3.3 million, changed N/A from the prior year.
Non-Current Debt held at $3.3 million in Q1 2016 per NAGE's latest filing.
Across five years, Non-Current Debt topped out at $3.3 million in Q1 2016 and bottomed at $3.3 million in Q1 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Niagen Bioscience	238.30 Mn	171.56 Mn	19.31 Mn	-

Historic Data

Download Data

Date	Value
Jan 2, 2016	3.35 Mn